Phenex raises €6M to achieve ROR success
This article was originally published in Scrip
Executive Summary
Phenex Pharmaceuticals, the Ludwigshafen-based nuclear receptor-focused drug discovery company, has raised €6 million in a series C round to finance its early-stage RORgt (Retinoic Acid Related Orphan Receptor gamma t) programme and the clinical development of the compound in its farnesoid X receptor (FXR) programme. In addition to its existing investors, Phenex has attracted money from high net worth individuals associated with the Boehringer family, one of Europe’s foremost pharmaceutical industry dynasties.